comparemela.com

Latest Breaking News On - Igg next generation - Page 1 : comparemela.com

Biotest increases EBIT to Euro 125 4 million in the first nine months of 2023

EQS-News: Biotest AG / Key word: 9 Month figures Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023 02.11.2023 / 08:00 CET/CEST The issuer.

United kingdomComunidad autonoma de catalunaUnited statesDirk neumMonika baumann buttkereitBiotest groupGrifols groupStandard of the german stock exchangeDrug administrationBiotest next levelBiotest nextBiologics license applicationIgg next generationQuarterly reportsPrime standardGerman stock

Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK -September 21, 2023 at 03:02 am EDT

EQS-News: Biotest AG / Key word: Regulatory Approval Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK 21.09.2023 / 09:00.

Comunidad autonoma de catalunaUnited kingdomMonika buttkereitDirk neumGrifols groupBiotest next levelSenior vice presidentGlobal salesIgg next generationPrime standard

Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo -Today at 03:02 am

EQS-News: Biotest AG / Key word: Regulatory Admission Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin.

United statesComunidad autonoma de catalunaReto bisazDirk neumMonika buttkereitGrifols groupDrug administrationBiologics license applicationIgg next generationBiotest next levelPrime standard

Biotest AG: Biotest increases EBIT to Euro 19 8 million in the first half of 2023

EQS-News: Biotest AG / Key word: Half Year Report Biotest AG: Biotest increases EBIT to Euro 19.8 million in the first half of 2023 10.08.2023 / 09:00. -Today at 03:01 am- MarketScreener

Comunidad autonoma de catalunaDirk neumMonika buttkereitBiotest groupDrug administrationStandard of the german stock exchangeGrifols groupBiotest next levelBiotest nextBiologics license applicationIgg next generationTechnology transferExecutive management boardManagement boardQuarterly reportsPrime standard

EQS-News: Biotest AG: Biotest increases EBIT to Euro 19 8 million in the first half of 2023

EQS-News: Biotest AG / Key word(s): Half Year Report Biotest AG: Biotest increases EBIT to Euro 19.8 million in th.

Comunidad autonoma de catalunaDirk neumMonika buttkereitStandard of the german stock exchangeGrifols groupBiotest groupDrug administrationBiotest next levelBiotest nextBiologics license applicationIgg next generationTechnology transferExecutive management boardManagement boardQuarterly reportsPrime standard

vimarsana © 2020. All Rights Reserved.